Advertisement
JOGC

No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy – An Addendum

Published:October 04, 2017DOI:https://doi.org/10.1016/j.jogc.2017.06.032

      Abstract

      Objective

      This technical update addendum reviews success rates and comparative evidence of the anticholinergic fesoterodine, as well as mechanism of action, safety profile, success rates, and comparative evidence of the β3 agonist mirabegron in the treatment of non-neurogenic overactive bladder syndrome (OAB). This adds to OAB pharmacotherapy recommendations initially published in 2012.

      Intended Users

      Residents and other trainees, primary care practitioners, gynaecologists, urologists, urogynaecologists, and other health care providers who assess, counsel, and treat women with OAB.

      Target Population

      Adult women with symptomatic OAB.

      Options

      This addition relates to fesoterodine, mirabegron, and anticholinergic-β3 agonist combination pharmacotherapy.

      Outcomes

      The outcomes of interest are clinical efficacy of fesoterodine compared with no treatment or other OAB therapies; mechanism of action and safety profile of mirabegron, clinical efficacy of mirabegron compared to no treatment or other OAB therapies; clinical efficacy of anticholinergic-β3 agonist combination pharmacotherapy for OAB.

      Evidence

      PubMed, Medline, and the Cochrane Database were searched using the key words “fesoterodine” and “mirabegron.” Results were restricted to English or French and human clinical and pharmacological research. Animal research and clinical studies including only male participants were excluded. Articles were included until the end of December 2016. Grey literature was not searched. Clinical practice guidelines, guidelines of specialty societies, and systematic reviews were included. RCTs and observational studies were included when evidence for the outcome of interest or in the target population was not available from systematic reviews. New studies not yet included in systematic reviews were also included. References of included articles were also searched to ensure comprehensive inclusion of relevant literature.

      Values

      The content and recommendations were drafted and agreed upon by the principal author, as well as members of the Urogynaecology Committee. The Board of the SOGC approved the final draft for publication. The quality of evidence was rated using the criteria described in the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology framework. The Summary of Findings is available upon request.

      Benefits, Harms, and/or Costs

      It is expected that this technical update will benefit patients with OAB by providing physicians and other interested health care providers with additional options for and knowledge of safe and effective OAB pharmacotherapy. The benefits clearly outweigh the potential harms or costs of implementation of this technical update, although there are no direct harms or costs identified.

      Updates

      “Evidence will be reviewed 5 years after publication to decide whether all or part of the document should be updated. However, if important new evidence is published prior to the 5-year cycle, the review process may be accelerated for a more rapid update of some recommendations.”

      Sponsors

      Not applicable.

      Recommendations

      • 1.
        Fesoterodine is recommended as a treatment for overactive bladder (Strong, High).
      • 2.
        Dose escalation of fesoterodine is recommended for improved clinical efficacy, as it is associated with significant subjective and objective clinical improvement, both short and long term (Strong, High).
      • 3.
        Fesoterodine is recommended as an anticholinergic of choice for overactive bladder symptoms in elderly and frail elderly (Strong, High).
      • 4.
        Fesoterodine is recommended for overactive bladder symptoms in patients with pre-existing cardiac concerns or cognitive dysfunction (Strong, Moderate).
      • 5.
        Fesoterodine is recommended for nocturnal overactive bladder symptoms to improve sleep quality (Conditional, High).
      • 6.
        Mirabegron is recommended as a treatment for overactive bladder (Conditional, High).
      • 7.
        Mirabegron is recommended for overactive bladder symptoms in patients with intolerable side effects or suboptimal response on anticholinergic therapy (Strong, Moderate).
      • 8.
        Mirabegron may be used in combination with solifenacin 5 mg for overactive bladder symptoms as an alternative to solifenacin 10 mg to decrease anticholinergic side effects of the higher dose solifenacin (Conditional, High).

      Key Words

      Abbreviations:

      CNS (central nervous system), FORTA (Fit fOR The Aged), OAB (overactive bladder syndrome), RCT (randomized control trial)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Obstetrics and Gynaecology Canada
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Haylen B.T.
        • de Ridder D.
        • Freeman R.M.
        • et al.
        An International Urogynecological Association (IUGA)/ International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.
        Int Urogynecol J. 2010; 21: 5-26
      1. GRADE Working Group Schünemann H. Brożek J. Guyatt G. Oxman A. The GRADE handbook. 2013 (Available at:)
        • Guyatt G.
        • Oxman A.D.
        • Akl E.A.
        • et al.
        GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.
        J Clin Epidemiol. 2011; 64: 383-394
        • McFerren S.C.
        • Gomelsky A.
        Treatment of overactive bladder in the elderly female: the case for trospium, oxybutynin, fesoterodine and darifenacin.
        Drugs Aging. 2015; 32: 809-819
        • Pfizer Canada Inc
        TOVIAZTM (fesoterodine fumarate extended-release tablets) monograph.
        (Pfizer Canada Inc. Updated on February 12; Available at:)
        • Chancellor M.B.
        • Staskin D.R.
        • Kay G.G.
        • et al.
        Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.
        Drugs Aging. 2012; 29: 259-273
      2. Health Canada Fesoterodine.
        (Available at:)
        • Chapple C.
        • Van Kerrebroeck P.
        • Tubaro A.
        • et al.
        Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
        Eur Urol. 2007; 52: 1204-1212
        • Nitti V.W.
        • Dmochowski R.R.
        • Sand P.K.
        • et al.
        Efficacy, safety, and tolerability of fesoterodine for overactive bladder syndrome.
        J Urol. 2007; 178: 2488-2494
        • Dmochowski R.R.
        • Peters K.M.
        • Morrow J.D.
        • et al.
        Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder.
        Urology. 2010; 75: 62-68
        • Chapple C.
        • Schneider T.
        • Haab F.
        • et al.
        Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
        BJU Int. 2014; 114: 418-426
        • Castro-Diaz D.
        • Miranda P.
        • Sanchez-Ballester F.
        • et al.
        Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study.
        BMC Urol. 2012; 12: 19
        • Van Kerrebroeck P.E.
        • Heesakkers J.
        • Berriman S.
        • et al.
        Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms.
        Int J Clin Pract. 2010; 64: 584-593
        • Sand P.K.
        • Heesakkers J.
        • Kraus S.R.
        • et al.
        Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies.
        Drugs Aging. 2012; 29: 119-131
        • Kelleher C.J.
        • Dmochowski R.R.
        • Berriman S.
        • et al.
        Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.
        BJU Int. 2012; 110: 392-400
        • Wagg A.
        • Khullar V.
        • Michel M.C.
        • et al.
        Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial.
        Neurourol Urodynam. 2014; 33: 106-114
        • Wagg A.
        • Oelke M.
        • Angulo J.C.
        • et al.
        Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.
        Drugs Aging. 2015; 32: 103-125
        • Oelke M.
        • Becher K.
        • Castro-Diaz D.
        • et al.
        Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014).
        Age Ageing. 2015; 44: 745-755
        • Wagg A.
        • Khullar V.
        • Marschall-Kehrel D.
        • et al.
        Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population.
        J Am Geriatr Soc. 2013; 61: 185-193
        • DuBeau C.E.
        • Kraus S.R.
        • Griebling T.L.
        • et al.
        Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled Trial.
        J Urol. 2014; 191: 395-404
        • Sicras-Mainar A.
        • Rejas J.
        • Navarro-Artieda R.
        • et al.
        Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.
        Int Urogynecol J. 2014; 25: 485-492
        • Ginsberg D.
        • Schneider T.
        • Kelleher C.
        • et al.
        Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
        BJU Int. 2013; 112: 373-385
        • Weiss J.P.
        • Jumadilova Z.
        • Johnson 2nd, T.M.
        • et al.
        Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency.
        J Urol. 2013; 189: 1396-1401
        • Yokoyama O.
        • Hiro S.
        • Hotta S.
        • et al.
        Efficacy of fesoterodine on nocturia and quality of sleep in Asian patients with overactive bladder.
        Urology. 2014; 83: 750-755
        • Kaplan S.A.
        • Schneider T.
        • Foote J.E.
        • et al.
        Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial.
        BJU Int. 2011; 107: 1432-1440
        • Madhuvrata P.
        • Cody J.D.
        • Ellis G.
        • et al.
        Which anticholinergic drug for overactive bladder symptoms in adults.
        Cochrane Database Syst Rev. 2012; (CD005429)
        • Kaplan S.A.
        • Cardozo L.
        • Herschorn S.
        • et al.
        Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER.
        Int J Clin Pract. 2014; 68: 1065-1073
        • Rai B.P.
        • Cody J.D.
        • Alhasso A.
        • et al.
        Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
        Cochrane Database Syst Rev. 2012; (CD003193)
        • Warren K.
        • Burden H.
        • Abrams P.
        Mirabegron in overactive bladder patients: efficacy review and update on drug safety.
        Ther Adv Drug Saf. 2016; 7: 204-216
        • Robinson D.
        • Thiagamoorthy G.
        • Cardozo L.
        A drug safety evaluation of mirabegron in the management of overactive bladder.
        Expert Opin Drug Saf. 2016; 15: 689-696
        • Andersson K.E.
        Pharmacology: on the mode of action of mirabegron.
        Nat Rev Urol. 2016; 13: 131-132
        • Alexandre E.C.
        • Kiguti L.R.
        • Calmasini F.B.
        • et al.
        Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade.
        Br J Pharmacol. 2016; 173: 415-428
        • Takusagawa S.
        • van Lier J.J.
        • Suzuki K.
        • et al.
        Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
        Drug Metab Dispos. 2012; 40: 815-824
        • Lee J.
        • Moy S.
        • Meijer J.
        • et al.
        Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
        Clin Drug Investig. 2013; 33: 429-440
        • Dickinson J.
        • Lewand M.
        • Sawamoto T.
        • et al.
        Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
        Clin Drug Investig. 2013; 33: 11-23
        • Lee J.
        • Zhang W.
        • Moy S.
        • et al.
        Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
        Clin Ther. 2013; 35: 333-341
        • Paśko P.
        • Rodacki T.
        • Domagała-Rodacka R.
        • et al.
        A short review of drug-food interactions of medicines treating overactive bladder syndrome.
        Int J Clin Pharm. 2016; 38: 1350-1356
        • Krhut J.
        • Martan A.
        • Zachoval R.
        • et al.
        Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females.
        Eur J Obstet Gynecol Reprod Biol. 2016; 196: 64-68
        • Groen-Wijnberg M.
        • van Dijk J.
        • Krauwinkel W.
        • et al.
        Pharmacokinetic interactions between mirabegron and metformin, warfarin, digoxin or combined oral contraceptives.
        Eur J Drug Metab Pharmacokinet. 2017; 42 ([e-pub ahead of print]): 417-429
        • Krauwinkel W.J.
        • Kerbusch V.M.
        • Meijer J.
        • et al.
        Evaluation of the pharmacokinetic interaction between the β3-adrenoceptor agonist mirabegron and the muscarinic receptor antagonist solifenacin in healthy subjects.
        Clin Pharmacol Drug Dev. 2013; 2: 255-263
        • Krauwinkel W.
        • Dickinson J.
        • Schaddelee M.
        • et al.
        The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
        Eur J Drug Metab Pharmacokinet. 2014; 39: 43-52
        • Rosa G.M.
        • Ferrero S.
        • Nitti V.W.
        • et al.
        Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.
        Eur Urol. 2016; 69: 311-323
        • Krauwinkel W.
        • van Dijk J.
        • Schaddelee M.
        • et al.
        Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
        Clin Ther. 2012; 34: 2144-2160
        • Wagg A.
        • Nitti V.W.
        • Kelleher C.
        • et al.
        Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
        Curr Med Res Opin. 2016; 32: 621-638
        • Orme S.
        • Morris V.
        • Gibson W.
        • et al.
        Managing urinary incontinence in patients with dementia: pharmacological treatment options and considerations.
        Drugs Aging. 2015; 32: 559-567
        • Novack G.D.
        • Lewis R.A.
        • Vogel R.
        • et al.
        Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers.
        J Ocul Pharmacol Ther. 2013; 29: 674-680
        • Chapple C.R.
        • Dvorak V.
        • Radziszewski P.
        • et al.
        A phase II dose-ranging study of mirabegron in patients with overactive bladder.
        Int Urogynecol J. 2013; 24: 1447-1458
        • Malik M.
        • van Gelderen E.M.
        • Lee J.H.
        • et al.
        Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.
        Clin Pharmacol Ther. 2012; 92: 696-706
        • Nitti V.W.
        • Chapple C.R.
        • Walters C.
        • et al.
        Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial.
        Int J Clin Pract. 2014; 68: 972-985
        • Katoh T.
        • Kuwamoto K.
        • Kato D.
        • et al.
        Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: results of a Japanese post-marketing study.
        Int J Urol. 2016; 23: 1009-1015
        • Ohyama K.
        • Inoue M.
        Association between selective beta-adrenergic drugs and blood pressure elevation: data mining of the Japanese Adverse Drug Event Report (JADER) database.
        Yakugaku Zasshi. 2016; 136: 1065-1071
        • Chapple C.R.
        • Kaplan S.A.
        • Mitcheson D.
        • et al.
        Randomized double-blind active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta3-adrenoceptor agonist in overactive bladder.
        Eur Urol. 2013; 63: 296-305
        • Kinjo M.
        • Sekiguchi Y.
        • Yoshimura Y.
        • et al.
        Long-term persistence with mirabegron versus solifenacin in women with overactive bladder: prospective, randomized trial.
        Low Urin Tract Symptoms. 2016; ([e-pub ahead of print])https://doi.org/10.1111/luts.12151
        • Duckett J.
        • Balachandran A.
        Tolerability and persistence in a large, prospective case series of women prescribed mirabegron.
        Int Urogynecol J. 2016; 27: 1163-1167
        • Wagg A.
        • Franks B.
        • Ramos B.
        • et al.
        Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada.
        Can Urol Assoc J. 2015; 9: 343-350
        • Pindoria N.
        • Malde S.
        • Nowers J.
        • et al.
        Persistence with mirabegron therapy for overactive bladder: a real life experience.
        Neurourol Urodyn. 2017; 36 ([e-pub ahead of print]): 404-408
        • Chapple C.
        • Amarenco G.
        • Lopez Aramburu M.
        • et al.
        A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
        Neurourol Urodyn. 2013; 32: 1116-1122
        • Khullar V.
        • Amarenco G.
        • Angulo J.C.
        • et al.
        Patient-reported outcomes with the β3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder.
        Neurourol Urodyn. 2016; 35: 987-994
        • Herschorn S.
        • Barkin J.
        • Castro-Diaz D.
        • et al.
        A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
        Urology. 2013; 82: 313-320
        • Yamaguchi O.
        • Marui E.
        • Kakizaki H.
        • et al.
        Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
        BJU Int. 2014; 113: 951-960
        • Khullar V.
        • Amarenco G.
        • Angulo J.C.
        • et al.
        Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
        Eur Urol. 2013; 63: 283-295
        • Wu T.
        • Duan X.
        • Cao C.X.
        • et al.
        The role of mirabegron in overactive bladder: a systematic review and meta-analysis.
        Urol Int. 2014; 93: 326-337
        • Kuo H.C.
        • Lee K.S.
        • Na Y.
        • et al.
        Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
        Neurourol Urodyn. 2015; 34: 685-692
        • Chapple C.
        • Khullar V.
        • Nitti V.W.
        • et al.
        Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.
        Eur Urol. 2015; 67: 11-14
        • Batista J.E.
        • Kölbl H.
        • Herschorn S.
        • et al.
        The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.
        Ther Adv Urol. 2015; 7: 167-179
        • Balachandran A.
        • Curtiss N.
        • Basu M.
        • et al.
        Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy?.
        Int Urogynecol J. 2015; 26: 367-372
        • Khullar V.
        • Cambronero J.
        • Angulo J.C.
        • et al.
        Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.
        BMC Urol. 2013; 13: 45
        • Balachandran A.
        • Duckett J.
        The efficacy and tolerability of mirabegron in a non-trial clinical setting.
        Eur J Obstet Gynecol Reprod Biol. 2016; 200: 63-67
        • Abrams P.
        • Kelleher C.
        • Staskin D.
        • et al.
        Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
        Eur Urol. 2015; 67: 577-588
        • Yamaguchi O.
        • Kakizaki H.
        • Homma Y.
        • et al.
        Safety and efficacy of mirabegron as add-on therapy in patients with overactive bladder treated with solifenacin: a post-marketing open-label study in Japan (MILAI study).
        BJU Int. 2015; 116: 612-622
        • Drake M.J.
        • Chapple C.
        • Esen A.A.
        • et al.
        Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE).
        Eur Urol. 2016; 70: 136-145